CureVac N.V. – NASDAQ:CVAC

Add to watchlist

$5.42

+2.25

+70.98%

Market closed

Open in about 2 hours

-2.76%

month

-2.76%

quarter

-25.24%

year

Market Cap	641.69M
Enterprise value	897.60M

P/E	-10.69
EV/Sales	9.25
EV/EBITDA	-9.56
Price/Sales	12.24
Price/Book	1.90
PEG ratio	0.04
EPS	-1.21

Revenue	58.42M
EBITDA	-246.22M
Income	-271.07M
Revenue Q/Q	73.55%
Revenue Y/Y	16.43%

Profit margin	-126.02%
Oper. margin	-137.65%
Gross margin	-79.47%
EBIT margin	-137.65%
EBITDA margin	-421.45%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

CureVac N.V. (NASDAQ:CVAC): Profit margin
Jun 2023	7.57M	-67.41M	-889.48%
Sep 2023	16.48M	-48.68M	-295.34%
Dec 2023	21.98M	-84.42M	-383.98%
Mar 2024	12.37M	-70.55M	-570.22%

CureVac N.V. Financials Estimate

Q Y

CureVac N.V. (NASDAQ:CVAC): Analyst Estimates
Dec 2023	21.98M	-84.42M	-383.98%
Mar 2024	12.37M	-70.55M	-570.22%
Sep 2025	19.60M	-51.93M	-264.96%
Dec 2025	21.16M	-48.76M	-230.45%

Analysts Price target
Financials & Ratios estimates

CureVac N.V. (NASDAQ:CVAC): Earnings per share (EPS)
2022-11-16	-0.24194	-0.2584

CureVac N.V. (NASDAQ:CVAC): Debt to assets
Jun 2023	899480000	250.43M	27.84%
Sep 2023	842566000	240.30M	28.52%
Dec 2023	788898887	271.53M	34.42%
Mar 2024	690433000	243.51M	35.27%

CureVac N.V. (NASDAQ:CVAC): Cash Flow
Jun 2023	-64.11M	-14.20M	-1.19M
Sep 2023	-60.58M	-13.42M	-1.21M
Dec 2023	-39.96M	-13.58M	-3.98M
Mar 2024	-96.55M	-5.08M	-1.12M

CureVac N.V. alternative data

CureVac N.V. (NASDAQ:CVAC): Employee count
Aug 2023	904
Sep 2023	904
Oct 2023	904
Nov 2023	904
Dec 2023	904
Jan 2024	904
Feb 2024	904
Mar 2024	904
Apr 2024	904
May 2024	904
Jun 2024	999
Jul 2024	999

CureVac N.V.
Hedge Funds Holdings Q3 2022

3.29% -0.91%

of CVAC is owned by hedge funds

75 -6

hedge funds hold CVAC stock

6.15M -1.69M

shares is hold by hedge funds

CVAC hedge funds holdings changes

CureVac N.V.
Earnings Call Transcripts

Quarter	Transcript
Q4 2023 24 Apr 2024	Q4 2023 Earnings Call Transcript
Q3 2023 14 Nov 2023	Q3 2023 Earnings Call Transcript
Q4 2022 25 Apr 2023	Q4 2022 Earnings Call Transcript
Q3 2022 16 Nov 2022	Q3 2022 Earnings Call Transcript

CVAC earnings call transcripts

CureVac N.V.
Executives

Insider	Age	Compensation
Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M. (1970) Chief Executive Officer & Member of Management Board	55	$680,250
Mr. Pierre Kemula B.Sc. (1974) MD, Chief Financial Officer & Member of Management Board	51	$661,730
Ms. Mariola Fotin-Mleczek (1968) Chief Technology Officer & Member of Management Board	57	$529,200
Dr. Igor Splawski M.Sc., Ph.D. (1969) Chief Scientific Officer & Member of Management Board	56	$446,040
Dr. Antony Blanc (1969) MD, Chief Bus. Officer & Chief Commercial Officer	56	$403,400

CureVac N.V.
Latest News

Monday, 16 December 2024
07:30	2 Small-Cap Stocks Set to Shine in a Bull Market	marketbeat.com
Wednesday, 20 November 2024
12:21	Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?	zacks.com
Tuesday, 12 November 2024
15:08	CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript	seekingalpha.com
07:20	CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update	accesswire.com
Thursday, 7 November 2024
07:30	CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024	accesswire.com
Monday, 4 November 2024
07:20	CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer	accesswire.com
07:15	CureVac to Present at the 12th International mRNA Health Conference	accesswire.com
Monday, 28 October 2024
08:10	CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting	accesswire.com
Tuesday, 8 October 2024
05:50	Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents	reuters.com
Friday, 13 September 2024
08:15	CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress	accesswire.com
Thursday, 12 September 2024
07:15	CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program	accesswire.com
Monday, 9 September 2024
07:15	CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress	accesswire.com
Thursday, 15 August 2024
07:30	CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update	accesswire.com
07:20	CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma	accesswire.com
07:15	CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board	accesswire.com
Thursday, 8 August 2024
11:00	CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?	zacks.com
Monday, 15 July 2024
13:01	CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?	zacks.com
Thursday, 11 July 2024
07:15	CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech	accesswire.com
07:00	Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer	businesswire.com
Wednesday, 3 July 2024
11:49	CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts	investorplace.com
10:18	GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines	barrons.com
10:09	CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK	investorplace.com
07:53	CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines	marketwatch.com
02:40	CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities	accesswire.com
02:40	GSK and CureVac to Restructure Collaboration into New Licensing Agreement	accesswire.com
02:26	GSK buys full rights to make COVID, influenza vaccines from CureVac	reuters.com
Monday, 24 June 2024
16:20	CureVac Announces Voting Results of General Meeting	accesswire.com
Friday, 10 May 2024
06:36	3 Stocks to Purge ASAP Before They're Pulled off Life Support	InvestorPlace
Thursday, 18 April 2024
07:15	CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024	Accesswire
Friday, 26 January 2024
10:35	Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 8 Jan 2025

CureVac: Latest GBM Data Bodes Well For Next Program Check Point
Seeking Alpha 24 Jul 2023

CureVac's CVGBM Trial: Promising Results Progress Pipeline
Seeking Alpha 22 May 2023

BioNTech: Able To Tap Into High Medical Need PD-L1 Refractory NSCLC Market
Seeking Alpha 25 Apr 2023

CureVac: Potential Of mRNA Tech Beyond Covid-19 Vaccine Development
Seeking Alpha 10 Aug 2021

Moderna: Only For Aggressive Investors
Seeking Alpha 14 Jun 2021

CureVac: The Moment Of Truth Is Delayed Until August
Seeking Alpha 8 Jun 2021

The Science Gives Moderna A Boost
Seeking Alpha 1 Jun 2021

CureVac: The Moment Of Truth Arrives
Seeking Alpha 28 May 2021

Moderna: Stuck Between CureVac And A Hard Place
Seeking Alpha 24 May 2021

BioNTech: The EU Deal Is Fantastic But Watch The Manufacturing Targets

Frequently Asked Questions (FAQ)

What's the price of CureVac N.V. stock today?

One share of CureVac N.V. stock can currently be purchased for approximately $5.42.
When is CureVac N.V.'s next earnings date?

Unfortunately, CureVac N.V.'s (CVAC) next earnings date is currently unknown.
Does CureVac N.V. pay dividends?

No, CureVac N.V. does not pay dividends.
How much money does CureVac N.V. make?

CureVac N.V. has a market capitalization of 641.69M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 20.26% to 53.76M US dollars. CureVac N.V. made a loss 260.17M US dollars in net income (profit) last year or -$0.26 on an earnings per share basis.
What is CureVac N.V.'s stock symbol?

CureVac N.V. is traded on the NASDAQ under the ticker symbol "CVAC".
What is CureVac N.V.'s primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of CureVac N.V.?

Shares of CureVac N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are CureVac N.V.'s key executives?
CureVac N.V.'s management team includes the following people:
- Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M. Chief Executive Officer & Member of Management Board(age: 55, pay: $680,250)
- Mr. Pierre Kemula B.Sc. MD, Chief Financial Officer & Member of Management Board(age: 51, pay: $661,730)
- Ms. Mariola Fotin-Mleczek Chief Technology Officer & Member of Management Board(age: 57, pay: $529,200)
- Dr. Igor Splawski M.Sc., Ph.D. Chief Scientific Officer & Member of Management Board(age: 56, pay: $446,040)
- Dr. Antony Blanc MD, Chief Bus. Officer & Chief Commercial Officer(age: 56, pay: $403,400)
How many employees does CureVac N.V. have?

As Jul 2024, CureVac N.V. employs 999 workers, which is 11% more then previous quarter.
When CureVac N.V. went public?

CureVac N.V. is publicly traded company for more then 5 years since IPO on 14 Aug 2020.
What is CureVac N.V.'s official website?

The official website for CureVac N.V. is curevac.com.
How can i contact CureVac N.V.?

CureVac N.V. can be reached via phone at +49 7071 98830.

CureVac N.V.

curevac.com

Exchange:

NASDAQ

Full time employees:

999

Industry:

Biotechnology

Sector:

Healthcare

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.

+49 7071 98830

Friedrich-Miescher-Strasse 15
Tübingen, 72076

CIK: 0001809122
ISIN: NL0015436031
CUSIP: N2451R105